Millennium Management’s enGene Therapeutics ENGN Stock Holding History
Bought
Maintained
Sold
Other funds holding ENGN
BCM
SL
ACA
Millennium Management's ENGN Position: Q3 2026 in Review
Millennium Management reduced its enGene Therapeutics (ENGN) stake by 81% in Q3 2026, selling an estimated $1.45M and leaving 181,619 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #5220.
Millennium Management first reported a position in ENGN in Q2 2025 and has held it in 6 quarters since. The position peaked at $13.5M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.
- Millennium Management held 181,619 shares of enGene Therapeutics worth $363K as of Q3 2026.
- Millennium Management sold 785,008 enGene Therapeutics shares in Q3 2026, an estimated $1.45M.
- enGene Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #5220 holding.
- Millennium Management first reported a position in enGene Therapeutics in Q2 2025 and has held it in 6 quarters since.
- Millennium Management's enGene Therapeutics position peaked at $13.5M in Q4 2025.
- 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.
Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.